Growth Strategies

Nastech Pharmaceutical Co. Inc. is planning an expansion of its research facilities in Bothell, WA, and the relocation of its corporate headquarters to Bothell. Occupancy of the 27,000-square-foot facility will begin in June and continue through the end of 2002. The new facility will also include manufacturing capacity for up to 50 million dosage units per year, a significant increase over current capacity. Nastech currently occupies 37,148 square feet of research and manufacturing space at 45 Adams Ave. and 45 Davids Ave, in Hauppauge, NY. Nastech will maintain certain R&D activities at its present site, and is adding manufacturing capacity in Hauppauge for up to 5 million dosage units per year. These activities will remain in Hauppauge for the foreseeable future. "Nastech is on a growth trajectory that requires additional staff, laboratory, and manufacturing capacity," stated Steven C. Quay, chairman, president, and CEO of Nastech. "The Seattle, Washington, area is an evolving biotechnology hub with a tremendous pool of scientific talent, which will further expand our R&D activities."